MDRPEDIA RECORDELITE · TIER IILIVING
Patrick Soon-Shiong
Oncology · NantHealth · Los Angeles, South Africa
- h-index (OpenAlex)
- 55
- Papers on record
- 10
- Citations to these papers
- 6,053
- Stature
- Tier II
EVIDENCE RECORD
What this record is built on
Compared with the register: Surgery · South Africa · How it works
I · SCHOLARSHIP
- h-index
- 55 · 70th pct
- Papers on record
- 10
- Citations received
- 6,053
II · PRACTICE
- Licence
- Not yet checked
- Board certification
- —
- Registration ID
- —
- Institutions
- 1
III · LEARNING & TEACHING
- Trainees traced
- Not yet traced
- Mentors traced
- Not yet traced
- Invited talks
- —
IV · PEER STANDING
- Honours
- —
- Techniques pioneered
- 1
- Ethics mark
- Not yet audited
Not on this record by design:Star ratingsAnonymous reviewsPaid placement
Record
Patrick Soon-Shiong is a South African-American surgeon and biotech entrepreneur who developed Abraxane, a nanoparticle albumin-bound paclitaxel that improved cancer treatment. Also pioneered one of the first whole-organ pancreas transplants.
IN PLAIN WORDS
- Pioneered the Abraxane (nab-paclitaxel), a technique still used by doctors worldwide
- Research is cited 6K+ times by other doctors and scientists
- Currently at NantHealth in Los Angeles, South Africa
What they treat and study
SPECIALTIES
CLINICAL KNOWLEDGE AND PROCEDURES
Institutions
- NantHealth
QUESTIONS YOU MIGHT ASK AT A FIRST VISIT
- Is a procedure needed now, or can medicines and lifestyle changes help first?
- What are the risks and benefits of each option for someone like me?
- How many similar cases does your team see, and who will be involved in my care?
- Who do I contact if symptoms come back after treatment?
Landmark papers
- Papers on record
- 10
- Citations received
- 6,053
PUBLISHED IN Clinical Cancer Research · Journal of Clinical Oncology · Advanced Drug Delivery Reviews · The Lancet · PubMed
- 2006Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.Clinical Cancer Researchdoi 10.1158/1078-0432.ccr-05-16341,156 citations
- 2011Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncologydoi 10.1200/jco.2011.36.57421,043 citations
- 2008Protein nanoparticles as drug carriers in clinical medicineAdvanced Drug Delivery Reviewsdoi 10.1016/j.addr.2007.08.044762 citations
- 1994Insulin independence in a type 1 diabetic patient after encapsulated islet transplantationThe Lancetdoi 10.1016/s0140-6736(94)90067-1658 citations
- 2002Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.PubMed630 citations
Show all 10 papersShow fewer papers
- 1996Alginate polycation microcapsulesBiomaterialsdoi 10.1016/0142-9612(96)84680-1510 citations
- 2009SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer PatientsTranslational Oncologydoi 10.1593/tlo.09109392 citations
- 1991Induction of Cytokine Production from Human Monocytes Stimulated with AlginateJournal of Immunotherapydoi 10.1097/00002371-199108000-00007390 citations
- 1996Alginate polycation microcapsulesBiomaterialsdoi 10.1016/0142-9612(96)85907-2272 citations
- 2018Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomesScientific Reportsdoi 10.1038/s41598-018-31707-9240 citations
Techniques pioneered
- Abraxane (nab-paclitaxel)
Career
- 2005FDA approved AbraxaneNanoparticle albumin-bound paclitaxel approved for breast cancer treatment
Lineage
We haven't traced this physician's mentors and trainees yet. If you trained with them, you can add to the record.Contribute lineage
FOR THE DOCTOR
Are you Patrick Soon-Shiong?
Claim this record to correct details, add your lineage and teaching, and embed your seal. Claims are checked against your registration before anything changes.